Supplementary Materials

1. Variation filtering criteria:

(1) The variants with AF < 5% defined as the rare SNPs and InDels were kept. And the "P" and "LP" level variants in HGMD & ClinVar were kept.

(2) SNPs were annotated as the conserved nucleotides by requiring scaled CADD scores \geq 15; and were predicted to be damaging by prediction algorithm. The criteria we used for the prediction algorithms are: REVEL score > 0.75. Indel variants annotated as loss-of-function variants (frameshift variants, splicing variants, stop-gain, and stop-loss variants) were kept.

(3) After filtering variants with frequency and conservation criteria, XX genes with XX variants were kept and then used to perform Disease annotation.

2. Primer sequences used for Sanger sequencing and Real-time Fluorescence Quantitative PCR

Primer Name	Sequence	Size of	Reagent	Condition
		Amplicon		
LRP6-2570-YD	AGGGCTCAACCGTGAA	471 bp	MIX	Touch
X-F	GTT			down
LRP6-2570-YD	TGCATTCCCCTACCCTTT		MIX	Touch
X-R	AACC			down

3. Protocols for PCR amplification and Real-time Fluorescence Quantitative PCR

(1) PCR amplification condition

Experiment	PCR conditions	PCR enzyme and
system		buffer
	Touch-down protocol:	TAKARA
Touch	The initial step at 95 °C, 5 min; followed by	PrimeSTAR® HS
down	21 cycles: 95 °C, 30 sec \rightarrow 70°C, 30 sec, with	DNA Polymerase (with
	decreasing 1°C per cycle \rightarrow 72°C, 30 sec;	0.5M Betaine)

```
followed by 25 cycles: 95 °C, 30 sec\rightarrow50°C,
30 sec\rightarrow72°C, 30 sec; final extension at
72 °C, 10 min.
```

(2) Fluorescence Quantitative PCR method and condition

At 48 h after transfection, cells were harvested and total RNA was extracted with an RNeasy Mini Kit (QIAGEN). Reverse transcription was performed with the Prime Script RT Reagent Kit with the gDNA Eraser (Takara).

The expression level was assessed by Fluorescence Quantitative PCR using SYBR Premis Ex Taq II(Perfect Real Time) (Takara) with ABI 7500 system. Data are presented as mean \pm standard deviation of three independent real-time PCR experiments. The PCR cycle was as follows: 10 min 95° C, 1 cycle; 10 s 95° C, 30 s 60° C+fluorescence acquisition, 55 cycles. Values for each gene were normalized to expression level of beta-actin gene (ACTB) via the 2- $\Delta\Delta$ CT method.

Primers for internal control:

ACTB-F		GGCATGGGTCAGAAGGATT
	ACTB-R	TGGTGCCAGATTTTCTCCA

4. Results of functional prediction of the missense mutation

Mutation taster: disease causing; polyphen2: PROBABLY DAMAGING with a score of 0.987 (sensitivity: 0.73; specificity: 0.96); PROVEAN: Variant PROVEAN score Prediction (cutoff= -2.5) R857H -4.042 Deleterious (see images below)



JCVI J. CRAIG VENTER INSTITUTE*

mutation t@sting

Prediction

M 37

Summary

disease causing

amino acid sequence changed
 protein features (might be) affected
 splice site changes

Aodel: simple_aae, prob: 0.99999999999848	3
---	---

hyperlink

analysed issue	analysis result
name of alteration	no title
alteration (phys. location)	chr12.12311984C>T show variant in all transcripts IGV
HGNC symbol	LRP6
Ensembl transcript ID	ENST00000261349
Genbank transcript ID	NM_002336
UniProt peptide	075581
alteration type	single base exchange
alteration region	CDS
DNA changes	c.2570G>A cDNA.2647G>A g.107963G>A
AA changes	R857H Score: 29 explain score(s)
position(s) of altered AA if AA alteration in CDS	857
frameshift	no

PROVEAN

_				JCVI
 → PROVEAN Tools PROVEAN Protein PROVEAN Protein Batch Human Mouse PROVEAN Genome Variants Human Mouse → About → FAQ 	PROVEAN PROVEAN • Query • Suppo Numbe • Score t (1) Def -Varian • Varian (2) Hov	Prediction - Job ID: 1: sequence (fasta) rting sequences to use r of sequences: 199 (fas r of clusters: 30 thresholds for predicti ault threshold is -2.5, thi ts with a score equal to o ts with a score above -2. v to use a more stringen	d) 164857894393673 ed for prediction ta, E-values) on at is: or below -2.5 are considered "deleterious," 5 are considered "neutral."	
→ News	Variant	PROVEAN score	Prediction (cutoff= -2.5)	
→ Download	R857H	-4.042	Deleterious	
→Help	- Cubmitte	d at 21/22/22 EDT. Supr	How Mar 21 2021	
→ Contact Us	 Started a Einished 	at 21:22:24 EDT, Sunday, at 21:22:46 EDT, Sunday,	, Mar 21, 2021 . Mar 21, 2021	
→ Related Links	* The resul	ts are kept for 48 hour	5.	

	UTI.		Home	About Help Downloads Batch query WHES3.db
PolyPhen-2	2 report f	or Q9	P2D7	/ R971H
Query				
Protein Acc	Position	AA1	AA2	Description
Q9P2D7	971	R	H.	Canonical, RecName. Full=Dynein heavy chain 1, axonemal, AtlName. Full=Axonemal beta dynein heavy chain 1, AtlName. Full=Ciliary dynein heavy chain 1, AtlName. Full=
Results				
Prediction	Confidenc	e		
HumDiv				
				This mutation is predicted to be PROBABLY DAMAGING with a score of 0.987 (sensitivity: 0.73; specificity: 0.96)
				0,00 0,20 0,40 0,60 0,00 1,00

5. Detailed methods and original results of the Western Blot (WB) experiment(1) WB methods

Cells were washed with cold PBS twice. Then, the total proteins were extracted by RIPA lysis buffer (Beyotime, Jiangsu, China). Lysed cells were centrifugated at 12,000 × g for 10 min and the protein containing supernatant were collected. The quantification of protein was performed by a BCA assay kit (Abcam, USA). Quantified proteins were then lorded and separated by 10% SDS-PAGE and transferred to PVDF membranes (Millipore Corporation, USA). 5% non-fat milk (BD Bioscience, USA) was applied to block the membrane. Then the membranes were incubated with the primary antibodies against LRP6 (#2560, 1:1000, Cell Signaling Technology), Phospho-LRP6 (#2568, 1:1000, Cell Signaling Technology), GAPDH (60004-1-Ig, 1:20000, proteintech) was incubated overnight at 4 degrees, the membrane was treated with the secondary antibodies (goat anti-rabbit, 1:5000; goat anti-mouse, 1:5000) at room temperature for 2 h. Last, an enhanced chemiluminescence Western blotting system (Pierce, Biotechnology Inc., Rockford, USA) was utilized for quantification.

(2) Original results (raw bands)



LRP6 (MW, KDa: 180; 210)



p-LRP6 (MW, KDa: 210)



GAPDH (MW, KDa: 36)

6. Stomatological images of the 4 patients in this study.

II-2





II-3





III-2













